David Kekich - Stem Cell Therapy Breakthrough Centagen is developing technology to help millions of people who suffer from chronic pain, disease and injury with an advanced form of adult stem cell therapy. For more information go to http://www.indiegogo.comFrom:CentagenViews:187 80ratingsTime:02:35More inScience Technology Originally posted here: David Kekich - Stem Cell Therapy Breakthrough - Video … Continue reading →

What Areas of Arthritis Do Autologous Stem Cells Work Best For? What types of conditions and what types of arthritis are most amenable to autologous stem cell treatment. Some joints do better than others. Why that is is still a matter of conjecture. It's important to realize stem cells don't work for every condition.From:Nathan WeiViews:0 1ratingsTime:02:00More inScience Technology Read the original post: What Areas of Arthritis Do Autologous Stem Cells Work Best For? - Video … Continue reading →

Conference explores Deaf identity and genetics - Remark! Deaf News Remark! Deaf News - The best BSL Deaf News, presented in British Sign Language ( BSL ), for the latest Deaf news go to http://www.remark.uk.com 21st December 2011 Conference explores Deaf identity and genetics Last weekend, Bristol's Centre for Deaf Studies hosted a conference that marked the end of a two year project focusing on genetics and the concept of Deafhood. Deafhood is a culturo-linguistic model that refers to the beliefs and practices of the Deaf community and people who use sign language, as well as their language, culture and history. The concept of Deafhood is the opposite of what is known as the'medical model' of deafness; that deafness is essentially something that should be fixed. The conference, called'Sleepwalking into Eugenics' arrived in the midst of a range of developments in deafness research, such as the stem cell treatment that has'cured' deafness in gerbils, that signals the possibility of deafness being'cured' in humans in the future. The conference was organised by Paddy Ladd and Steve Emery because they felt that the views of the Deaf community were being ignored in genetic … Continue reading →

LA JOLLA, Calif., Nov. 14, 2012 /PRNewswire/ --StemGenex, Inc. -- November is National Alzheimer's Disease Awareness Month and is dedicated to raising the awareness of this neurodegenerative disorder. Alzheimer's currently affects 5 million people in the U.S. and 35 million across the globe, and due to aging populations, this number is growing rapidly. To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/stemgenex-on-the-forefront-of-adult-stem-cell-based-therapy-for-alzheimers-179326951.html Currently pharmacological treatments only manage symptoms and offer no cure for the disease. Alternatively, adult stem cells have shown great promise to potentially replace lost or support damaged brain cells due to their remarkable ability of differentiating into many cell types. StemGenex, a U.S. based company, is pioneering new therapeutic methods for adipose-derived adult stem cells. StemGenex has a major emphasis on Alzheimer's disease and other conditions such as Parkinson's, COPD, Multiple Sclerosis and Type 1 Diabetes. For over 6 years StemGenex has been conducting studies to advance Alzheimer's adult stem cell treatment protocols in efforts to alleviate the disease's symptoms. Some innovations at StemGenex include: Rita Alexander, the President of StemGenex, says, "We are encouraged and excited with our progress in developing methods and protocols for adipose derived adult stem cell treatments for Alzheimer's … Continue reading →

MD Stem Cells is pleased to announce the first treatment in the United States of a patient with eye disease using the new injection technique for stem cells they helped pioneer. Dr Steven Levy, President of MD Stem Cells, http://www.mdstemcells.com, indicated the procedure went very smoothly. The patient is anticipating a positive response within the next few months. Fort Lauderdale, FL (PRWEB) November 14, 2012 "We have helped a number of eye patients utilize Bone Marrow Derived Stem Cells or BMSC for retinal and optic nerve diseases and have observed macular degeneration, myopic degeneration, hereditary retinopathies, optic nerve and glaucoma patients, among others, have visual improvements following treatment. Our retinal surgeon has used both subretinal surgery and different injection techniques in the past for the placement of BMSC in ocular disease. We collaboratively developed a dual injection technique that we believe takes advantage of the recently identified active vascular expulsion mechanism of cell transmigration and are very excited about our ability to deliver the BMSC to the RPE, retina and optic nerve. Dr Levy mentioned that the new technique has already been used by the retinal surgeon for a number of patients in Europe and after careful preparation is now … Continue reading →

Jonathan Milner, CEO of antibodies hothouse Abcam, has joined other angels in backing an exciting new stem cell company in Cambridge UK. DefiniGEN is one of the first commercial opportunities to arise in the area of stem cells. The ability to generate stem cells by reprogramming cells from patients skin has revolutionised this area of research. These cells, known as human induced pluripotent stem cells (hIPSC), can be differentiated into almost any cell type, allowing the opportunity to have a ready source of human cells for testing new therapies. DefiniGEN has been formed to supply hIPSC-derived cells to the drug discovery and regenerative medicine sectors. The company is based on the research of Dr Ludovic Vallier, Dr Tamir Rashid and Professor Roger Pedersen of the Anne McLaren Laboratory of Regenerative Medicine. The hIPSC-derived cells produced by DefiniGEN show many of the functional characteristics of primary cells, are highly reproducible and can be made in large quantities, making them ideal for liver toxicity testing, which is a major cause of drug candidate failure. The universitys enterprise fund has also invested 50k in Inotec AMD a spin-out from the Department of Materials Science & Metallurgy, specialising in the treatment of chronic wounds. … Continue reading →